Bio- and Nano-Technology Center (BNTC) faculty members are renowned in the field, receiving accolades, awards, and funding for their work to translate biology and nanoscience discoveries into biopharmaceuticals, nanomedicines, and biomaterials.
Explore the links below for news, awards, and funding updates that highlight our faculty members' most recent achievements.
Center News
- BNTC Collaborates with NIST to Evaluate Biomanufacturing Technologies
Date Published: November 13, 2020
Quality measurements with benchtop nuclear magnetic resonance (NMR) is compatible with manufacturing, but its potential in the pharmaceutical industry has yet to be realized. To help accelerate adoption of benchtop NMR methods, the BNTC and NIST have initiated an inter-lab comparison of the benchtop NMR measurements for characterizing model liquid dosage forms of pharmaceutical products. The goal of this study is to validate that, across different instrument platforms and different laboratories and operators, these measurements are reliable, reproducible, and informative methods for characterizing pharmaceutical products.
- SOP's Yu Leads Research to Assure Vaccine Quality at Point-of-Care
Date Published: June 10, 2020
New non-invasive quality assurance method developed by Dr. Bruce Yu and his team offers more effective way to detect freezing events in vaccines at the point-of-care.
- Nanoparticle Therapy Shows Promise with Breast Cancer
Date Published: January 23, 2020
Researchers at the University of Maryland School of Medicine developed a new nanoparticle drug formulation that targets a specific receptor on cancer cells and appears to be more effective than a standard nanoparticle therapy currently on the market to treat metastatic breast cancer.
- Decreased Nonspecific Adhesivity, Receptor-Targeted Therapeutic Nanoparticles for Primary and Metastatic Breast Cancer
Date Published: January 15, 2020
Study provides new insights into methods for effective development of therapeutic nanoparticles as well as support the continued development of the DART platform for primary and metastatic tumors.
- TEDCO's Maryland Innovation Initiative Infuses $2.63M in New Round of Projects
Date Published: January 8, 2020
New technology commercialization projects and spin-outs funded.
- IBBR Researchers Receive $1.1M from FDA and NIIMBL to Support Biomanufacturing Innovation
Date Published: November 19, 2019
SOP Yu receives FDA contract to develop nondestructive analytics for vaccines and complex drugs. This three-year project applies the water proton NMR technology to evaluate product consistency and freezing behavior of vaccines, insulin products and emulsion drugs.
- DART Therapeutic Platform Technology for Treating Fn14-Positive Cancers
Date Published: June 13, 2016
The discovery of unique cell surface proteins associated with certain tumors has facilitated new approaches for nanocarrier design and payload delivery; specifically, the capability of targeting and selectively killing tumor cells while sparing healthy tissue.
Faculty Awards
| Faculty Member | Recent Awards |
|---|---|
| Christopher Jewel |
|
| Ryan Pearson |
|
Funding Updates
Grants
- Improving Multiple Sclerosis Patient Quality of Life Using Microneedles
NIH # R01 AI144667 (NIAID), 06/2019-05/2023
Principal Investigator: Christopher Jewell
- Programming immune function through modular assembly of polyionic immune signals
NIH # R01 EB027143 (NIBIB), 03/2019-12/2022
Principal Investigator: Christopher Jewell -
Harnessing biomaterials to study the link between local lymph node function and systemic tolerance
NIH # R01 EB026896 (NIBIB), 04/2018-12/2021
Principal Investigator: Christopher Jewell -
Tunable Assembly of Regulatory Immune Signals to Promote Myelin-specific Tolerance
U.S. Veteran Affairs # I01 BX003690 (BLR&D), 07/2017-06/2021
Principal Investigator: Christopher Jewell -
Engineered Ensemble Nanoimmunotherapies for Cancer
NIH # R01 CA226171 (NCI), 12/2018-11/2022
Principal Investigator: Christopher Jewell -
Engineering B cell modulating vaccines for T cell cancer immunotherapy
2020 Innovative Collaboration Pilot Grant (UMB Institute for Clinical and Translational Science (1UL1TR003098)
Principal Investigator: Ryan Pearson -
CFZ Delivery to Colon with EK101 for CDI Treatment
2020 Maryland Industrial Partnerships Phase I (Mtech)
Principal Investigator: Ryan Pearson -
Formulation Development for Bone Control Therapy
2019 Maryland Industrial Partnerships Phase II (Mtech)
Principal Investigator: Ryan Pearson -
Programming immune cell sensitivity towards Toll-like receptor activation
2019 New Investigator Award (American Association of Colleges of Pharmacy)
Principal Investigator: Ryan Pearson